Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03976752 · ClinicalTrials.gov registry record · Phase 1
Body Compartment Pharmacokinetics of Anti-retroviral Agents That May be Considered for Future On-demand Peri-exposure HIV Prophylaxis Regimens
A Phase 1 study of HIV/AIDS, sponsored by Emory University.
- Completed
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
- 1
- Study location
NCT03976752: Completed Phase 1 study of HIV/AIDS, sponsored by Emory University.
NCT03976752 is a Phase 1 study of HIV/AIDS that has completed, run by Emory University. The registered enrollment target is 41 participants, below the 33,180-participant average among 61 other HIV/AIDS trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03976752, a Phase 1 study of HIV/AIDS, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is being conducted to determine if the uptake of anti-HIV medication, called Genvoya®, at different time-frames, is different at several body sites, including mucosal tissues. This medication might be considered for on-demand PEP regimens in the future.
Primary Outcome
Median drug concentrations of the TFV component of Genvoya were determined at baseline and at each of the protocol specified follow-up time points. Concentrations below the limit of quantification (LOQ) are assigned a value of zero.
Conditions Studied
Interventions
- DRUG Genvoya
Study Locations (1)
Georgia
- Hope Clinic - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2019-03-13 |
| Est. Completion | 2019-09-20 |
| Phase | Phase 1 |
What the finished NCT03976752 record still lists
NCT03976752 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 33,180-participant average among 61 other HIV/AIDS trials with a reported enrollment target (100% lower).
The record links to 1 condition, with HIV/AIDS appearing as the primary indexed condition, and to 1 intervention - of which Genvoya is the first listed.
NCT03976752 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT03976752 about?
NCT03976752 is a clinical study titled "Body Compartment Pharmacokinetics of Anti-retroviral Agents That May be Considered for Future On-demand Peri-exposure HIV Prophylaxis Regimens". This study is being conducted to determine if the uptake of anti-HIV medication, called Genvoya®, at different time-frames, is different at several body sites, including mucosal tissues. This medication might be considered for on-demand PEP regimens in the future.
What is the current status of trial NCT03976752?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2019-03-13. Estimated completion is 2019-09-20.
What conditions does trial NCT03976752 study?
This clinical trial studies the following conditions: HIV/AIDS.
What interventions are being tested in trial NCT03976752?
The interventions under investigation include: Genvoya (DRUG).
Who is sponsoring clinical trial NCT03976752?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03976752 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV/AIDS
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03976752's enrollment target sits among peer trials
41 47th of 61 higher than 15 of 61 other HIV/AIDS trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV/AIDS trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Combinatorial Therapy to Induce an HIV Remission
ACTIVE NOT RECRUITING · Phase 1
-
Study in Healthy Males to Measure Darunavir and Etravirine in Blood, Seminal Fluid, and Rectal Tissue
COMPLETED · Phase 1
-
Transgender Youth and PrEP: PK, Safety, Uptake & Adherence - PK Study
COMPLETED · Phase 1
-
Relative Mitochondrial Toxicity of Tenofovir Alafenamide (TAF) vs. Tenofovir Disoproxil Fumarate (TDF)
COMPLETED · Phase 1
-
A Mobile Gaming App to Improve Adherence to PrEP
RECRUITING · NA
-
LinkPositively+ A Mobile Health App Delivered Intervention to Improve HIV Care Outcomes Among Black Women Affected by Mental Health and Violence
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI